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re-analysed if not analysed by intention-to-treat. The summary
effect estimate (Relative Risk, RR) was calculated by meta-analy-
sis using a ﬁxed effects model by the Mantel-Haenszel method.
The quality of RCTs included in the meta-analysis was judged
according to the method of randomisation and concealment of
allocation of treatments (as this is the element of RCT design
likely to introduce the most bias). Publication bias was assessed
using funnel plots. RESULTS: Of the 133 papers initially iden-
tiﬁed in the literature search, only 8 were found to be head-to-
head comparisons of a standard dose of PPI compared with
esomeprazole 40 mg. This total was reduced to six when the
quality of the RCTs was assessed. From the 6 trials, a meta-
analysis of endoscopic healing rates of esomeprazole 40 mg com-
pared with standard-dose PPIs gave the following RESULTS: At
4 weeks, RR 0.92 (95% CI: 0.90 to 0.94, p < 0.00001); at 8
weeks, RR 0.95 (95% CI: 0.94 to 0.97, p < 0.00001). The effect
of using all eight trials in the meta-analysis made small numeri-
cal differences to the overall estimates but did not change the
direction or make a signiﬁcant difference non-signiﬁcant. Publi-
cation bias did not appear to have a signiﬁcant impact on the
results, as there was no apparent asymmetry identiﬁed in the
assessment of funnel plots. CONCLUSIONS: Esomeprazole
demonstrates signiﬁcantly higher endoscopic healing rates when
compared to standard-dose PPIs.
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OBJECTIVE: To show the efﬁcacy of orally administered
esomeprazole 40 mg (ESO) in patients with erosive gastro-
oesophageal reﬂux disease (GERD) in Mexico. METHODS: We
conducted an open label, prospective cohort study in 22 centers
in Mexico, between June 2001 and July 2002, with patients
being 18–86 years old, diagnosed with endoscopy-conﬁrmed
erosive (GERD) and classiﬁed according to Los Angeles Classi-
ﬁcation (LAC). Patients were treated with ESO 40 mg for a 4–8
week period. According to LAC, effectiveness was measured by
the reﬂux-oesophagitis healing at 4 and 8 weeks, deﬁned as the
absence of macroscopic mucosal lesions. Symptoms and general
evaluation of the treatment were secondary end points. Presence
of Helicobacter pylori was assessed by clotest. The study was
analyzed using the ITT population. Healing at the 4 and 8 week
endpoints was assessed with the McNemar test (p < 0.05, 95%
CI). RESULTS: A total of 213 patients were included in the
study: 53.52% were males, and the average age was 44.2 years
(±14.63). 78.88% were diagnosed with mild to moderated
GERD (Grades A & B LAC), and 38.97% were positive for 
Helicobacter pylori. Using gastro-oesophageal endoscopy as 
the assessment method, GERD healing rate after the 4 and 
8 weeks period with esomeprazole 40 mg were 88.73%
(84.48%–92.98%, 95% CI) and 94.84% (91.87%–97.81%,
95% CI) respectively. No serious adverse events were reported.
Treatment with esomeprazole 40 mg was well tolerated. CON-
CLUSIONS: Esomeprazole 40 mg proved to be effective and
secure for the GERD treatment in the Mexican patients.
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OBJECTIVES: To compare the clinical and cost-effectiveness of
esomeprazole and other PPI (omeprazole, lansoprazole, panto-
prazole and rabeprazole) in patients with GERD. METHODS:
The clinical effectiveness analysis according Cochrane Collabo-
ration guidelines was performed. Cost-effectiveness decision
model was performed from a payer’s perspective, with a time
horizon of 8 weeks. RESULTS: 8, 13, 6, and 3 RCT comparing
esomeprazole to lansoprazole, omeprazole, pantoprazole and
raboprazole were included. Esomeprazole 40 mg was signiﬁ-
cantly more effective compared to lansoprazole 30 mg and
omeprazole 20 mg in healing reﬂux esophagitis after 4 and 8
weeks (OR = 1.25 and 1.29 vs. lansoprazole; OR = 1.84 and
2.10 vs. omeprazole). Esomeprazole is also more effective than
lansoprazole and omeprazole for variables evaluating reﬂux
symptoms. Compared to pantoprazole 40 mg, esomeprazole 40
mg was statistically signiﬁcantly more effective in terms of
healing erosive oesophagitis after 4–6 and 8–10 weeks (OR =
1.35 and 1.36, respectively), time to reach sustained heartburn
resolution and proportion of heartburn-free days. Result of a
single trial showed that pantoprazole resulted in faster ﬁrst-time
relief from GERD-related symptoms than esomeprazole. Based
on a single study comparing esomeprazole 20 mg and rabepra-
zole 10 mg in patients with non-erosive GERD, both treatments
had similar efﬁcacy in relief of symptoms. Triple therapy regi-
mens with either esomeprazole or omeprazole were similarly
effective in eradicating Helicobacter pylori. The safety analysis
showed no signiﬁcant differences in the frequency of adverse
events between esompeprazole and other PPI except for
headaches, which occurred more frequently in the desloratadine
group than in the lansoprazole group. The ICER for esomepra-
zole per additional patient healed after 8 weeks was 7858 PLN
(vs lansoprazole), 2608 PLN (vs lansoprazole) and 6274 PLN
(vs. pantoprazole). CONCLUSIONS: Esomeprazole is at least as
effective as other PPI in the treatment of GERD.
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OBJECTIVES: Mycophenolate mofetil (MMF) has been associ-
ated with increased risk of gastrointestinal (GI) complications in
transplant recipients. Our aim was to assess the risk of GI med-
ication use in heart transplant patients receiving MMF and their
health care costs over a two-year period. METHODS: US com-
mercial claims data for 233 patients receiving heart transplants
between 1995 and 2005 were linked to data from the Organ Pro-
curement Transplant Network. Patients were placed into two
groups: received MMF (MMF group) and did not (non-MMF
group). MMF recipients were identiﬁed as having ≥1 pharmacy
claim post-transplant for MMF. For the MMF group, use of GI
medications was deﬁned as having ≥1 prescription (H2 antago-
nists, proton pump inhibitors, and miscellaneous GI agents)
during the year following the initial claim for MMF. For those
in the non-MMF group, the commensurate 1-year period post-
transplant in which the GI claim occurred was deﬁned based on
